PUBLICATION
Global Business Reports
APLA Sustainability Special Report
February 04, 2019
In a context of increasing population and growing middle classes, the use of plastic has become so common in everyday life that it has generated some unwanted side effects. The solution to tackle the plastic waste issue and reach a perfect ‘circular economy’ situation involves several components, including more stringent regulations, the development of the right infrastructure and handling processes for recycling, education at all levels of society, and an innovation push by the industry to ensure products are easily reused and recycled.
RELATED INTERVIEWS MORE INTERVIEWS
Haldor Topsoe discusses the potential for energy transition in Latin America.
The Mexican Union of Agrochemicals Manufacturers and Formulators (UMFFAAC) describes the main themes impacting its members.
"Preparing the industry to seize the opportunity is crucial. Just as the US experienced stages during the shale boom, Argentina must follow similar steps."
Cristian García of PROCCYT explains the dynamics influencing Mexico’s crop protecting sector.
RELATED ARTICLES MORE ARTICLES
Sustainability: a Comprehensive Look
APLA Sustainability Special Report
The ‘S’ word is a wide-reaching concept that demands a joint effort on many fronts by governments, the industry, and the wider population.
Solid Demand Factors but Political Risk Rising
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Rising exports and a growing middle class bode well for Mexico’s chemical demand, but NAFTA renegotiations, Presidential elections and the slow pace of energy reforms are present concerns.
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
